How well does Africa's trial portfolio match WHO priority diseases?
WHO Priority Match
Low
NTD Trial Gap
Extreme
NCD Alignment
Poor
Mental Health
Near zero
Key Finding
Non-communicable diseases — cardiovascular (1,426), cancer (2,182), and diabetes (760) — received research attention misaligned with their growing contribution to African mortality.
Regional Comparison
Mental Health — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Mental Health — Computed Statistics
Africa: 174 | US: 2,996 | Europe: 1,494 | Ratio: 17.2x
Africa share: 3.7% | HHI4-region = 0.518 | Shannon H = 1.28 bits
Community: AF 203 vs US 1,969 (9.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Africa's trial portfolio is heavily skewed toward HIV, malaria, and TB while neglecting the WHO's broader priority list. Neglected tropical diseases — affecting hundreds of millions of Africans — account for only 5% of trials. Non-communicable diseases receive 12% despite causing 37% of deaths. Mental health, affecting tens of millions, has virtually no trial presence. The alignment between research investment and disease burden remains poor.
The Evidence 145 words · target 156
In global health priority-setting, does Africa's clinical trial portfolio align with the WHO priority disease list and Sustainable Development Goal health targets? This alignment analysis compared condition-specific trial volumes across 23,873 African registrations on ClinicalTrials.gov to WHO essential medicines and SDG 3 priority conditions. Africa's trial portfolio was heavily skewed toward HIV (1,793 trials), malaria (531 trials), and tuberculosis (489 trials) while neglecting WHO-designated priorities including mental health (174 trials), neglected tropical diseases (12 trials), and epilepsy (73 trials). Non-communicable diseases — cardiovascular (1,426), cancer (2,182), and diabetes (760) — received research attention misaligned with their growing contribution to African mortality. Only malaria and tuberculosis research showed Africa exceeding the global average trial density. These findings demonstrate systematic misalignment between Africa's research portfolio and both WHO priorities and the epidemiological transition. Interpretation is limited by the mapping between ClinicalTrials.gov condition categories and WHO priority classifications.
Sentence Structure
Question
In global health priority-setting, does Africa's clinical trial portfolio align with the WHO priority disease list and Sustainable Development Goal health targets?
Dataset
This alignment analysis compared condition-specific trial volumes across 23,873 African registrations on ClinicalTrials.gov to WHO essential medicines and SDG 3 priority conditions.
Method
Africa's trial portfolio was heavily skewed toward HIV (1,793 trials), malaria (531 trials), and tuberculosis (489 trials) while neglecting WHO-designated priorities including mental health (174 trials), neglected tropical diseases (12 trials), and epilepsy (73 trials).
Primary Result
Non-communicable diseases — cardiovascular (1,426), cancer (2,182), and diabetes (760) — received research attention misaligned with their growing contribution to African mortality.
Robustness
Only malaria and tuberculosis research showed Africa exceeding the global average trial density.
Interpretation
These findings demonstrate systematic misalignment between Africa's research portfolio and both WHO priorities and the epidemiological transition.
Boundary
Interpretation is limited by the mapping between ClinicalTrials.gov condition categories and WHO priority classifications.